Paper I
2024 August (Supplementary) (2010 Scheme) · 40 marks · 120 min

Question

Aspirin in the secondary prevention of Ischaemic heart disease

Q101 marksShort Answers

Answer

Low-dose aspirin irreversibly acetylates and inhibits platelet cyclooxygenase-1, blocking thromboxane A2 synthesis for the entire lifespan of the platelet (platelets cannot synthesize new enzyme), while relatively sparing endothelial COX-mediated prostacyclin production at low doses. This produces a net antiplatelet, antithrombotic effect that reduces the risk of recurrent coronary thrombotic events — the rationale for its use in secondary prevention of ischemic heart disease.

Other Years Asked


Revise MBBS
Preview